| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/09/2011 | EP2292630A1 O2-substituted 1- (2-carboxylato)pyrrolidin-1-yl diazen-1-ium-1,2-diolates |
| 03/09/2011 | EP2292622A1 New crystalline form of a triazolo(4,5-d)pyrimidine compound |
| 03/09/2011 | EP2292617A1 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinase inhibitors |
| 03/09/2011 | EP2292615A1 Quinazoline compounds |
| 03/09/2011 | EP2292614A1 Substituted pyrimidines as aurora kinase inhibitors |
| 03/09/2011 | EP2292613A1 Dihydroindolinone derivatives |
| 03/09/2011 | EP2292610A1 Macrolides with VEGF transcription suppression activity |
| 03/09/2011 | EP2292593A2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors |
| 03/09/2011 | EP2292587A1 Pharmaceutical composition for inhibiting the transcription factor inducible by hypoxia, modulators of pathological processes of angiogenesis, oncogenesis, inflammation, apoptosis, and cellular therapy |
| 03/09/2011 | EP2292576A2 Retinoids useful in the treatment of cancer and for reducing serum triglycerides |
| 03/09/2011 | EP2292275A2 Protecting therapeutic compositions from host-mediated inactivation |
| 03/09/2011 | EP2292273A2 Remodeling and glycoconjugation of peptides |
| 03/09/2011 | EP2292271A2 Remodelling and glycoconjugation of an antibody |
| 03/09/2011 | EP2292251A1 Combination therapy using anti-angiogenic agents and TNF-alpha |
| 03/09/2011 | EP2292242A1 A scutellarin derivative, the preparing process, the pharmaceutical composition and the use thereof |
| 03/09/2011 | EP2292241A1 A scutellarin derivative, the preparing process, the pharmaceutical composition and the use thereof |
| 03/09/2011 | EP2292234A1 Compositions comprising quinazoline derivatives, preparation methods and uses thereof |
| 03/09/2011 | EP2292233A2 Pharmaceutical uses of N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine |
| 03/09/2011 | EP2292232A1 Beta-amino tetrahydroimidazo(1,2-A)pyrazines and tetrahydrotriazolo(4,3-A)pyrazines for use in the treatment of diabetes type II |
| 03/09/2011 | EP2292226A2 The use of a polyphenol for the treatment of a cancerous or pre-cancerous lesion of the skin |
| 03/09/2011 | EP2292221A2 Formulations of suberoylanilide hydroxamic acid and methods for producing same |
| 03/09/2011 | EP2292184A1 Implantable stent prosthesis |
| 03/09/2011 | EP2291520A1 Nucleic acid molecule and method of targeting gene expression to gliomas |
| 03/09/2011 | EP2291509A2 Microfluidic isolation of tumor cells or other rare cells from whole blood or other liquids |
| 03/09/2011 | EP2291406A1 An anti-cancer cytotoxic monoclonal antibody |
| 03/09/2011 | EP2291402A2 Antibodies against domains of laminin-332 |
| 03/09/2011 | EP2291401A2 Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof |
| 03/09/2011 | EP2291398A1 Her3 as a determinant for the prognosis of melanoma |
| 03/09/2011 | EP2291390A1 New optically pure compounds for improved therapeutic efficiency |
| 03/09/2011 | EP2291376A2 Naphthyridininones as aurora kinase inhibitors |
| 03/09/2011 | EP2291375A1 Pyrrolopyridinylpyrimidin-2-ylamine derivatives |
| 03/09/2011 | EP2291365A1 5-substituted isoindoline compounds |
| 03/09/2011 | EP2291355A2 Novel tetrahydroquinolines as aromatase inhibitors |
| 03/09/2011 | EP2291350A2 Compositions and methods for preparing and using same |
| 03/09/2011 | EP2291199A2 Capsulating system binding to nucleolin |
| 03/09/2011 | EP2291193A1 Preparation of intermediates useful in the syntheis of 2'-cyano-2'-deoxy-n4-palmitoyl-1-beta-d-arabinofuranosylcytosine |
| 03/09/2011 | EP2291192A2 Anticancer methods using extracts of anemerrhena asphodeloides bungle |
| 03/09/2011 | EP2291186A2 Materials and methods for suppressing and/or treating neurofibroma and related tumors |
| 03/09/2011 | EP2173349B1 Antitumour combinations containing a vegf inhibiting agent and irinotecan |
| 03/09/2011 | EP2144904B1 (s,r)-3-phenyl-4,5 dihydro-5-isoxazole acetic acid-nitric oxide and use thereof as anti-cancer and antiviral agent |
| 03/09/2011 | EP1971338B1 Combination of zd6474 and pemetrexed |
| 03/09/2011 | EP1954281B1 Cancer treatment method |
| 03/09/2011 | EP1912954B1 Novel cysteine protease inhibitors and their therapeutic applications |
| 03/09/2011 | EP1888122B1 A method for preparing a stable immunogenic product comprising antigenic heterocomplexes of tnf alpha and a carrier protein |
| 03/09/2011 | EP1874770B1 Phenylacetamides suitable as protein kinase inhibitors |
| 03/09/2011 | EP1842857B1 Mutant interferon proteins and use thereof |
| 03/09/2011 | EP1838712B1 Pyrazolopyrimidine compounds as antitumor agents |
| 03/09/2011 | EP1732920B1 Thiophene derivatives as chk 1 inhibitors |
| 03/09/2011 | EP1732602B1 Detecting the mcsp-surface expression of a cell |
| 03/09/2011 | EP1688498B1 A recombinant protein with cancer suppression action, its encoding gene and use |
| 03/09/2011 | EP1491206B9 Use of peptide derivatives for inducing cell differentiation |
| 03/09/2011 | EP1385466B1 Oncolytic virus therapy |
| 03/09/2011 | EP1355910B1 Formulation of boronic acid compounds |
| 03/09/2011 | EP1135178B1 Polymeric coatings with controlled delivery active agents |
| 03/09/2011 | CN1980891B Indole, benzofuran and benzothiophene derivatives as selective androgen receptor modulators (SARMS) |
| 03/09/2011 | CN1824255B Curcuma zedoary oil solid lipid nano-particle and its preparation method |
| 03/09/2011 | CN1582274B Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
| 03/09/2011 | CN101984056A RNA interference target RNA of long non-coding RNA related to human melanoma cells and application thereof |
| 03/09/2011 | CN101983968A Preparation method of sepia oligopeptide by enzymatic hydrolysis and application thereof |
| 03/09/2011 | CN101983964A Compound with antibacterial activity and antitumor activity and preparation method and applications thereof |
| 03/09/2011 | CN101983719A Novel medicament for treating lung cancer |
| 03/09/2011 | CN101983718A Novel medicament for treating liver cancer |
| 03/09/2011 | CN101983690A Novel traditional Chinese medicine for treating rhinocarcinoma |
| 03/09/2011 | CN101326167B Pyridiazinone derivatives for tumour treatment |
| 03/09/2011 | CN101311166B Tyrosine kinase restraining agent, preparation method thereof and use |
| 03/09/2011 | CN101234100B Application of naphthoquinone compounds |
| 03/08/2011 | USRE42211 Relating to binding proteins for recognition of DNA |
| 03/08/2011 | US7902441 Group of recessive oncogenes, Fus1, 101F6, Gene 21 (NPRL2), Gene 26 (CACNA2D2), Luca 1 (HYAL1), Luca 2 (HYAL2), PL6 ,123F2 (RaSSFI), SEM A3 and Beta* (BLU), defined by homozygous deletion in lung cancer, have been located, isolated at 3p21.3 |
| 03/08/2011 | US7902361 Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy |
| 03/08/2011 | US7902255 γ-butyrolactone compound and pharmaceutical composition thereof |
| 03/08/2011 | US7902241 Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| 03/08/2011 | US7902234 Thiadiazoline derivative |
| 03/08/2011 | US7902223 Phenyl derivatives as factor XA inhibitors |
| 03/08/2011 | US7902193 Phthalazinone derivatives |
| 03/08/2011 | US7902187 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| 03/08/2011 | US7902186 Substituted 5-phenyl-3,6-dihydro-2-oxo-6H-1,3,4-thiadiazines |
| 03/08/2011 | US7902149 Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins |
| 03/08/2011 | US7902144 Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same |
| 03/08/2011 | US7901917 Human aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis |
| 03/08/2011 | US7901894 Kinase inhibitors |
| 03/08/2011 | US7901879 Also stimulating interleukin-18 or GM-CSF by administering lactoferrin |
| 03/08/2011 | US7901716 Active fraction having anti-cancer and anti-metastasis isolated from leaves and stems of ginseng |
| 03/08/2011 | US7901709 Active agent, a gel-phase lipid bilayer membrane of a phospholipid and a surface active agent contained in the bilayer membrane; increasing the percentage of active agent released at the phase transition temperature of the lipid bilayer |
| 03/08/2011 | US7901707 Biodegradable biocompatible implant and method of manufacturing same |
| 03/08/2011 | CA2634381C Carbonylamino pyrrolopyrazoles, potent kinase inhibitors |
| 03/08/2011 | CA2486915C Active fraction having anti-cancer and anti-metastasis isolated from leaves and stems of ginseng |
| 03/08/2011 | CA2464721C Nitrogenous (tetrahydropyridyl) (alkyl) heterocycles with tnf activity |
| 03/08/2011 | CA2460313C Bisphenylsulfanyl and sulphonate compounds and use thereof for elevating hdl cholesterol levels |
| 03/08/2011 | CA2422291C Targeted alpha particle therapy using actinium-225 conjugates |
| 03/08/2011 | CA2420899C Hydroxamate derivatives useful as deacetylase inhibitors |
| 03/08/2011 | CA2415396C 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications |
| 03/08/2011 | CA2413334C Stabilized interleukin 2 |
| 03/08/2011 | CA2338504C Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| 03/08/2011 | CA2137377C Retinal pigmented epithelium derived neurotrophic factor |
| 03/03/2011 | WO2011026153A2 Inotilone derivatives as coherent biological response modifier (cbmr) |
| 03/03/2011 | WO2011025968A1 1h-pyrazolo [ 3, 4-b] pyridine compounds for inhibiting raf kinase |
| 03/03/2011 | WO2011025965A1 Raf inhibitor compounds and methods of use thereof |
| 03/03/2011 | WO2011025951A1 Raf inhibitor compounds and methods of use thereof |
| 03/03/2011 | WO2011025947A1 Raf inhibitor compounds and methods of use thereof |
| 03/03/2011 | WO2011025940A1 Raf inhibitor compounds and methods of use thereof |